Keros Historical Balance Sheet

KROS Stock

USD 11.01 0.28 2.48%

Trend analysis of Keros Therapeutics balance sheet accounts such as Total Current Liabilities of 16.2 M provides information on Keros Therapeutics' total assets, liabilities, and equity, which is the actual value of Keros Therapeutics to its prevalent stockholders. By breaking down trends over time using Keros Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Keros Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Keros Therapeutics is a good buy for the upcoming year.

Keros Therapeutics Inventory

16.97 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

About Keros Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Keros Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Keros Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Keros Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Keros currently owns. An asset can also be divided into two categories, current and non-current.

Keros Therapeutics Balance Sheet Chart

At this time, Keros Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.7 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 166.3 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Deferred Long Term Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Keros Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Keros Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Keros Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Keros Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most accounts from Keros Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Keros Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.At this time, Keros Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.7 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 166.3 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	13.3M	14.4M	18.9M	19.8M
Total Assets	306.8M	370.0M	615.9M	646.7M

Short Long Term Debt Total Total Assets

Keros Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.87	0.97	0.72	1.0	-0.81	0.84	0.92	0.74	-1.0	-0.97	0.85	1.0	0.91	0.88	0.94	0.73	1.0	0.8	0.91	0.73	0.85	0.96	0.92	0.95	0.99
Short Long Term Debt Total	0.87		0.95	0.79	0.86	-0.61	0.63	0.99	0.86	-0.85	-0.95	0.77	0.86	0.98	0.97	0.94	0.59	0.86	0.66	0.82	0.59	0.98	0.83	0.99	0.94	0.86
Other Current Liab	0.97	0.95		0.83	0.96	-0.76	0.8	0.98	0.84	-0.95	-0.99	0.88	0.96	0.98	0.94	0.99	0.69	0.96	0.75	0.92	0.69	0.93	0.94	0.98	0.96	0.96
Total Current Liabilities	0.72	0.79	0.83		0.7	-0.49	0.64	0.83	0.87	-0.72	-0.82	0.7	0.71	0.83	0.81	0.82	0.42	0.71	0.43	0.84	0.42	0.85	0.7	0.82	0.78	0.69
Total Stockholder Equity	1.0	0.86	0.96	0.7		-0.82	0.85	0.9	0.72	-1.0	-0.96	0.85	1.0	0.9	0.87	0.93	0.74	1.0	0.81	0.91	0.74	0.83	0.96	0.91	0.94	1.0
Other Liab	-0.81	-0.61	-0.76	-0.49	-0.82		-0.96	-0.68	-0.35	0.83	0.72	-0.93	-0.81	-0.69	-0.53	-0.76	-0.96	-0.81	-0.96	-0.88	-0.96	-0.53	-0.91	-0.67	-0.62	-0.82
Net Tangible Assets	0.84	0.63	0.8	0.64	0.85	-0.96		0.73	0.5	-0.87	-0.75	0.9	0.85	0.73	0.6	0.82	0.87	0.85	0.87	0.92	0.87	0.61	0.93	0.71	0.66	0.84
Property Plant And Equipment Net	0.92	0.99	0.98	0.83	0.9	-0.68	0.73		0.88	-0.9	-0.97	0.82	0.91	1.0	0.97	0.98	0.63	0.91	0.7	0.87	0.63	0.98	0.89	1.0	0.94	0.9
Current Deferred Revenue	0.74	0.86	0.84	0.87	0.72	-0.35	0.5	0.88		-0.71	-0.83	0.54	0.73	0.89	0.92	0.87	0.24	0.73	0.31	0.7	0.24	0.94	0.69	0.88	0.82	0.7
Net Debt	-1.0	-0.85	-0.95	-0.72	-1.0	0.83	-0.87	-0.9	-0.71		0.95	-0.86	-1.0	-0.9	-0.86	-0.93	-0.76	-1.0	-0.82	-0.92	-0.76	-0.82	-0.97	-0.9	-0.93	-0.99
Retained Earnings	-0.97	-0.95	-0.99	-0.82	-0.96	0.72	-0.75	-0.97	-0.83	0.95		-0.85	-0.96	-0.97	-0.95	-0.96	-0.67	-0.96	-0.74	-0.91	-0.67	-0.93	-0.91	-0.97	-0.99	-0.96
Accounts Payable	0.85	0.77	0.88	0.7	0.85	-0.93	0.9	0.82	0.54	-0.86	-0.85		0.84	0.82	0.68	0.86	0.9	0.84	0.91	0.94	0.9	0.7	0.92	0.8	0.76	0.84
Cash	1.0	0.86	0.96	0.71	1.0	-0.81	0.85	0.91	0.73	-1.0	-0.96	0.84		0.91	0.88	0.94	0.74	1.0	0.81	0.9	0.74	0.84	0.96	0.91	0.94	1.0
Non Current Assets Total	0.91	0.98	0.98	0.83	0.9	-0.69	0.73	1.0	0.89	-0.9	-0.97	0.82	0.91		0.97	0.99	0.63	0.91	0.7	0.88	0.63	0.98	0.9	1.0	0.93	0.9
Non Currrent Assets Other	0.88	0.97	0.94	0.81	0.87	-0.53	0.6	0.97	0.92	-0.86	-0.95	0.68	0.88	0.97		0.93	0.48	0.88	0.56	0.79	0.48	0.99	0.81	0.98	0.95	0.87
Other Assets	0.94	0.94	0.99	0.82	0.93	-0.76	0.82	0.98	0.87	-0.93	-0.96	0.86	0.94	0.99	0.93		0.67	0.94	0.73	0.92	0.67	0.94	0.95	0.98	0.91	0.93
Long Term Debt	0.73	0.59	0.69	0.42	0.74	-0.96	0.87	0.63	0.24	-0.76	-0.67	0.9	0.74	0.63	0.48	0.67		0.74	0.99	0.82	1.0	0.47	0.81	0.62	0.58	0.75
Cash And Short Term Investments	1.0	0.86	0.96	0.71	1.0	-0.81	0.85	0.91	0.73	-1.0	-0.96	0.84	1.0	0.91	0.88	0.94	0.74		0.81	0.9	0.74	0.84	0.96	0.91	0.94	1.0
Common Stock Total Equity	0.8	0.66	0.75	0.43	0.81	-0.96	0.87	0.7	0.31	-0.82	-0.74	0.91	0.81	0.7	0.56	0.73	0.99	0.81		0.83	0.99	0.55	0.86	0.69	0.67	0.82
Common Stock Shares Outstanding	0.91	0.82	0.92	0.84	0.91	-0.88	0.92	0.87	0.7	-0.92	-0.91	0.94	0.9	0.88	0.79	0.92	0.82	0.9	0.83		0.82	0.79	0.94	0.86	0.83	0.89
Long Term Debt Total	0.73	0.59	0.69	0.42	0.74	-0.96	0.87	0.63	0.24	-0.76	-0.67	0.9	0.74	0.63	0.48	0.67	1.0	0.74	0.99	0.82		0.47	0.81	0.62	0.58	0.75
Non Current Liabilities Total	0.85	0.98	0.93	0.85	0.83	-0.53	0.61	0.98	0.94	-0.82	-0.93	0.7	0.84	0.98	0.99	0.94	0.47	0.84	0.55	0.79	0.47		0.8	0.98	0.91	0.83
Capital Surpluse	0.96	0.83	0.94	0.7	0.96	-0.91	0.93	0.89	0.69	-0.97	-0.91	0.92	0.96	0.9	0.81	0.95	0.81	0.96	0.86	0.94	0.81	0.8		0.89	0.85	0.95
Capital Lease Obligations	0.92	0.99	0.98	0.82	0.91	-0.67	0.71	1.0	0.88	-0.9	-0.97	0.8	0.91	1.0	0.98	0.98	0.62	0.91	0.69	0.86	0.62	0.98	0.89		0.95	0.91
Other Current Assets	0.95	0.94	0.96	0.78	0.94	-0.62	0.66	0.94	0.82	-0.93	-0.99	0.76	0.94	0.93	0.95	0.91	0.58	0.94	0.67	0.83	0.58	0.91	0.85	0.95		0.94
Other Stockholder Equity	0.99	0.86	0.96	0.69	1.0	-0.82	0.84	0.9	0.7	-0.99	-0.96	0.84	1.0	0.9	0.87	0.93	0.75	1.0	0.82	0.89	0.75	0.83	0.95	0.91	0.94

Click cells to compare fundamentals

Keros Therapeutics Account Relationship Matchups

Keros Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	269.4M	255.3M	306.8M	370.0M	615.9M	646.7M
Short Long Term Debt Total	899K	1.1M	13.3M	14.4M	18.9M	19.8M
Other Current Liab	4.0M	6.4M	12.2M	17.9M	20.9M	21.9M
Total Current Liabilities	7.2M	11.8M	16.5M	24.4M	27.5M	16.2M
Total Stockholder Equity	261.7M	243.2M	277.4M	332.2M	571.6M	600.1M
Net Tangible Assets	(19.4M)	261.7M	243.2M	277.4M	319.0M	166.3M
Property Plant And Equipment Net	1.6M	2.4M	17.6M	19.5M	23.5M	24.7M
Current Deferred Revenue	1.9M	4.4M	7.1M	17.3M	19.8M	20.8M
Net Debt	(265.0M)	(228.9M)	(265.8M)	(316.7M)	(541.1M)	(514.0M)
Retained Earnings	(65.0M)	(123.8M)	(228.4M)	(381.4M)	(568.8M)	(540.3M)
Accounts Payable	2.1M	3.6M	3.3M	5.5M	4.6M	3.4M
Cash	265.9M	230.0M	279.0M	331.1M	559.9M	587.9M
Non Current Assets Total	1.7M	3.8M	21.0M	22.7M	27.0M	28.3M
Other Assets	115K	993K	1.4M	3.4M	4.0M	4.2M
Cash And Short Term Investments	265.9M	230.0M	279.0M	331.1M	559.9M	587.9M
Common Stock Shares Outstanding	15.5M	23.3M	25.2M	29.4M	37.4M	23.4M
Liabilities And Stockholders Equity	269.4M	255.3M	306.8M	370.0M	615.9M	646.7M
Non Current Liabilities Total	538K	231K	12.8M	13.4M	16.9M	17.7M
Capital Surpluse	203K	326.7M	366.9M	505.9M	581.7M	610.8M
Capital Lease Obligations	899K	1.1M	13.3M	14.4M	18.9M	19.8M
Other Current Assets	1.6M	3.2M	5.9M	15.1M	26.2M	27.5M
Other Stockholder Equity	596.2M	366.9M	505.9M	713.6M	1.1B	1.2B
Total Liab	7.7M	12.1M	29.4M	37.8M	44.3M	23.8M
Net Invested Capital	261.7M	243.2M	277.4M	332.2M	571.6M	600.1M
Property Plant And Equipment Gross	1.6M	2.4M	17.6M	21.2M	26.4M	27.8M
Total Current Assets	267.7M	251.4M	285.8M	347.3M	588.9M	618.3M
Non Current Liabilities Other	119K	62K	231K	12.8M	14.7M	15.5M
Net Working Capital	260.5M	239.6M	269.2M	322.9M	561.4M	589.5M
Short Term Debt	846K	1.7M	910K	1.0M	2.0M	1.1M
Property Plant Equipment	1.9M	1.6M	1.3M	2.0M	2.3M	1.8M
Net Receivables	216K	18M	841K	1.1M	2.7M	3.2M
Inventory	1.5M	3.1M	(841K)	14.1M	16.2M	17.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Keros Historical Balance Sheet

Keros Therapeutics Inventory

16.97 Million

About Keros Balance Sheet Analysis

Keros Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Deferred Long Term Liab

Keros Therapeutics balance sheet Correlations

Keros Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Keros Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Keros Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Debt	- 1.0	Total Assets
Other Current Assets	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Net Debt